Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin - DURECT/Curaxis

Drug Profile

Leuprorelin - DURECT/Curaxis

Alternative Names: DURIN™ leuprolide implant; DURIN™-leuprolide; Leuprorelin - Curaxis/DURECT; Leuprorelin - DURECT/Voyager; Leuprorelin - Voyager/DURECT; Memryte implant; VP4896

Latest Information Update: 18 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DURECT Corporation; Voyager Pharmaceutical
  • Developer Curaxis Pharmaceutical Corporation
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Alzheimer's disease

Most Recent Events

  • 23 Sep 2010 Curaxis enters into an equity line agreement with Southridge Partners
  • 19 Aug 2010 Voyager Pharmaceutical completes reverse merger and becomes publicly traded company called Curaxis Pharmaceutical Corporation; funding secured to resume clinical development of leuprolin
  • 07 Nov 2006 A pivotal phase III trial of Memryte™ implant for the treatment of Alzheimer's disease ends early to enable analysis of efficacy data
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top